Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1054 - Characterization of a Novel Tumor-Suppressor Gene CHL1 at 3p26.3 in Esophageal Squamous Cell Carcinoma


11 Sep 2017


Poster display session


Translational Research;  Oesophageal Cancer


Hongyan Wang


Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363


H. Wang

Author affiliations

  • Internal Medicine, Henan Cancer Hospital, 450008 - Zhengzhou/CN


Abstract 1054


The major histologic subtype of esophageal cancer, esophageal squamous cell carcinoma (ESCC), is one of the most common cancers and has been ranked as the sixth leading cause of cancer-related deaths in the world. Using human genome U133 Plus 2.0 GeneChip, we identified gene down-regulation of Cell adhesion molecule L1 like (CHL1) located at 3p26.3 in ESCC. We analysed its down-regulated expression, biological effects and prognostic significance in ESCC.


To determine whether the down-regulation of CHL1 was associated with aberrant methylation. Methylation-specific PCR (MSP) was performed in ESCCs and their corresponding non-tumor tissues, as well as ESCC cell lines. Loss of heterozygosity status of CHL1 was evaluated by fluorescence in situ hybridization (FISH). The effects of CHL1 re-expression or knockdown were determined in proliferation, invasion and metastasis assay. CHL1 target genes and related pathways were identified by protein mass spectrometry, co-immunoprecipitation (Co-IP), immunofluorescence (IF) and western-blot. Clinical impact of CHL1 down-regulated expression was assessed in 287 patients with ESCC.


The results showed that down-regulation of CHL1 was significantly associated with allele loss (14/21) and promoter methylation (19/21; P


CHL1 plays a pivotal tumor suppressive role in ESCC; its down-regulated expression is an independent prognostic factor of patient with ESCC.

Clinical trial identification

Legal entity responsible for the study

Henan Cancer Hospital




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.